BIIB's BG-12 Review Period Extended Zacks.com Meanwhile, Biogen and partner Abbott Labs (ABT - Analyst Report) moved another MS candidate, daclizumab, into a two-year phase III study (DECIDE) in July 2010, with results due in 2014. Daclizumab is being evaluated as a once-monthly or bi-weekly ... |
